Shares of Endo International (ENDP) declined 2.27% to close the trading session on Sep 22 at $66.16 following Auxilium Pharmaceuticals’ (AUXL) rejection of Endo’s unsolicited takeover bid. Auxilium Pharma after reviewing Endo’s $2.2 billion or 28.10 per share offer turned it down as it felt that the proposal grossly undervalued the company. However, Auxilium Pharma did not shut the door permanently as far as a … Continue reading Biotech Stock in News: Auxilium Pharmaceuticals Not Favoring Endo Bid

Amarin Corporation (AMRN) tumbled 17.7% after the company announced that the FDA’s Office of New Drugs (OND) denied the company’s appeal regarding the rescission of the Special Protocol Assessment (SPA) covering the phase III ANCHOR study on Vascepa. Vascepa has been available in the U.S. since Jan 2013 as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥ 500 mg/dL) … Continue reading Biotech News: Amarin Stock Plummets after the FDA Denies Major Appeal

Medivation, Inc (MDVN) and partner Astellas Pharma Inc (ALPMY) received a major boost with the FDA expanding the label of their prostate cancer treatment, Xtandi. Xtandi, which was earlier approved for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who had previously received docetaxel (chemotherapy), can now be used in patients with metastatic CRPC who have not received chemotherapy. The prostate cancer market … Continue reading Biotech Stock in Focus: Medivation-Astellas’ Xtandi’s Label Expanded

Orexigen Therapeutics, Inc. finally gained FDA approval for its weight loss drug, Contrave (NB32, naltrexone hydrochloride and bupropion hydrochloride extended-release tablets). We expect investors to react positively to the news. The FDA cleared Contrave as an adjunct to a healthy diet (low on calories) and physical activity for chronic weight management in obese (Body Mass Index, or BMI, ≥ 30) or overweight (BMI ≥ 27) … Continue reading Biotech Stock News: Orexigen’s Obesity Drug Contrave Approved, Stock Set to Rise High

Last week was eventful for the biotech sector with highlights including a couple of FDA approvals (Xtandi’s label expansion and Contrave) and a positive FDA panel outcome (Natpara). However, the biggest gainer was Avanir Pharmaceuticals ( AVNR ), which came out with positive phase II data for the treatment of agitation in patients with Alzheimer’s disease. Shares were up 85.3%. Overall, the NASDAQ Biotechnology Index … Continue reading A Look At the Best Performing Biotech Stocks For this Week

NPS Pharmaceuticals (NPSP) received encouraging news when the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA recommended the approval of the company’s hormone replacement therapy Natpara (rhPTH [1-84]). NPS Pharma’s candidate was recommended for long-term use to treat patients suffering from hypoparathyroidism, a rare disease caused by the deficiency/absence of parathyroid hormone, by 8 of the 13 panel members. The positive opinion rendered … Continue reading Biotech Stocks in News: NPS Pharmaceuticals’ Natpara Gets Positive Review, Stock Set For a High